Acusphere Announces FDA Acceptance Of Imagify? NDA For Detection Of Coronary Artery Disease

Acusphere, Inc. (NASDAQ: ACUS) announced that the New Drug Application (NDA) for approval to market its lead product candidate, Imagify? (Perflubutane Polymer Microspheres for Injectable Suspension), has been accepted for review by the U.S. Food & Drug Administration (FDA). Imagify is an ultrasound imaging agent for the detection of coronary artery disease, the leading cause of death in the United States.

More: continued here

Filed under: Cardiovascular on July 4th, 2008